FDA issues final guidance on genetically engineered animal regulation
As part of the U.S. Food and Drug Administration’s ongoing efforts to ensure that heparin for patients remains safe, the government seized 11 lots of heparin from Celsus Laboratories Inc. in Cincinnati, Ohio. The five lots of Heparin Sodium Active Pharmaceutical Ingredient (API) and six lots of Heparin Lithium were seized at the FDA’s request
Full Post: FDA seizes Heparin from Cincinnati manufacturer
The U.S. Food and Drug Administration has issued a final guidance for industry on the regulation of genetically engineered (GE) animals under the new animal drug provisions of the Federal Food, Drug and Cosmetic Act (FFDCA).
The guidance, titled “The Regulation of Genetically Engineered Animals Containing Heritable rDNA Constructs,” clarifies the FDA’s statutory and regulatory authority, and provides recommendations to producers of GE animals to help them meet their obligations and responsibilities under the law.
Genetic engineering generally refers to the use of recombinant DNA (rDNA) techniques to introduce new characteristics or traits into an organism. When scientists splice together pieces of DNA and introduce a spliced DNA segment into an organism to give the organism new properties, it is called rDNA technology. The spliced piece of DNA is called the rDNA construct. A GE animal is one that contains an rDNA construct intended to give the animal new characteristics or traits.
“Genetic engineering is a cutting edge technology that holds substantial promise for improving the health and well being of people as well as animals. In this document, the agency has articulated a scientifically robust interpretation of statutory requirements,” said Randall Lutter, Ph.D., deputy commissioner for policy. “This guidance will help the FDA efficiently review applications for products from GE animals to ensure their safety and efficacy.”
The FDA released the draft guidance in September 2008 with a 60-day public comment period, and received about 28,000 comments. The agency has summarized and responded to these comments on the Web site listed below.
The FDA’s Center for Veterinary Medicine (CVM) has been working with developers of GE animals on both early stage and more mature applications.
“At this time, it is our intent to hold public scientific advisory committee meetings prior to making decisions on GE animal-related applications” said Bernadette Dunham, D.V.M., Ph.D., director of CVM.
The FFDCA defines “articles (other than food) intended to affect the structure or any function of the body of man or other animals” as drugs. An rDNA construct that is in a GE animal and is intended to affect the animal’s structure or function meets the definition of an animal drug, whether the animal is intended for food, or used to produce another substance. Developers of these animals must demonstrate that the construct and any new products expressed from the inserted construct are safe for the health of the GE animal and, if they are food animals, for food consumption.
The U.S. Food and Drug Administration has issued three guidances designed to help ensure the safety of FDA-regulated products in the supply chain. The documents issued today include the following: Final Guidance for Industry on Voluntary Third-Party Certification Programs for Foods and Feeds; Draft Guidance for Industry on Submission of Laboratory Packages by Accredited Laboratories;
Full Post: New FDA guidelines for foods and feeds
Researchers from the National Institutes of Health and the Scripps Research Institute have found novel prion infectivity in white and brown fat tissues of mice. The study appears December 5 in the open-access journal PLoS Pathogens. Prion diseases, also known as transmissible spongiform encephalopathies, are infectious progressive fatal neurodegenerative diseases which affect humans as well
Full Post: Discovery of novel prion infectivity in white and brown fat tissues of mice
Osteotech, Inc. announced today that it has initiated a pivotal clinical trial for its DuraTech BioRegeneration Matrix. The first five patients in this 60-patient trial have already been enrolled. During the study’s initial cranial surgical procedures, the patients’ dura mater (the tough, outermost membrane surrounding the brain and spinal cord) was successfully repaired by surgeons
Full Post: Osteotech starts trial for DuraTech BioRegeneration Matrix
A study published in the scientific journal PLoS ONE highlights how the exploration of the ocean depths can benefit humankind. This is the story of a voyage of discovery, starting with marine animals that glow, the identification of the molecules responsible and their application as marker in living cells. Many marine organisms such as sea
Full Post: Biomedical research could benefit from deep sea
Salix Pharmaceuticals, Ltd. has announced that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older. Based on its review, the FDA has determined that
Full Post: Salix Pharmaceuticals receives FDA response for Balsalazide tablet